Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28799154 | 1.00 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL30667504 | 1.00 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL15229756 | 1.00 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL8793664 | 0.93 | RAF1 (0.45) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL4534203 | 0.92 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL27145420 | 0.92 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL4534200 | 0.92 | RAF1 (0.47) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL8746798 | 0.92 | KDM4E (0.49) | RAF1KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL12056332 | 0.88 | KDM4E (0.45) | KDM4EMEN1KMT2AHPGDMAOB | |
| SCHEMBL379266 | 0.83 | RAF1 (0.46) | RAF1KDM4EMAPK14HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874436-A | Preparation method of letromycin intermediate | 济宁学院 | 2023-10-13 | — | — | CN | claimed |
| EP-1893587-B1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | AICURIS GMBH & CO KG (DE) | 2012-01-25 | — | — | EP | claimed |
| US-8084604-B2 | Process for the preparation of dihydroquinazolines | Aicuris GmbH & Co., KG (DE) | 2011-12-27 | — | — | US | claimed |
| CN-117700339-A | Preparation method of letromycin intermediate | 江苏正济药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-116874436-A | Preparation method of letromycin intermediate | 济宁学院 | 2023-10-13 | — | — | CN | disclosed |
| US-9890128-B2 | Process for making substituted quinazoline compounds | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890128-B2 | Process for making substituted quinazoline compounds | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160311781-A1 | PROCESS FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| US-20160311781-A1 | PROCESS FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| WO-2015088931-A1 | PROCESS FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8816075-B2 | Process for the preparation of dihydroquinazolines | AICURIS GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-1893587-B1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | AICURIS GMBH & CO KG (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-1893587-B1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | AICURIS GMBH & CO KG (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-8084604-B2 | Process for the preparation of dihydroquinazolines | Aicuris GmbH & Co., KG (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084604-B2 | Process for the preparation of dihydroquinazolines | Aicuris GmbH & Co., KG (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084604-B2 | Process for the preparation of dihydroquinazolines | Aicuris GmbH & Co., KG (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090221822-A1 | Process for the Preparation of Dihydroquinazolines | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221822-A1 | Process for the Preparation of Dihydroquinazolines | BAYER HEALTHCARE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1893587-A1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | Bayer HealthCare AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133822-A1 | METHOD FOR PRODUCING DIHYDROQUINAZOLINES | BAYER HEALTHCARE AG (DE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311781-A1 | PROCESS FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS | CYP3A5, TPMT, MCM5 | RAF1 1666/4885KDM4E 1211/4885MEN1 359/4885 |
| US-20090221822-A1 | Process for the Preparation of Dihydroquinazolines | QDPR, DHPS, DHX15 | RAF1 2551/4885KDM4E 1466/4885MEN1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.